专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200230068A1 COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS 审中-公开
公开(公告)号：US20200230068A1
公开(公告)日：2020-07-23
申请号：US16641522
申请日：2018-08-08
申请人： Y. Joseph MO , Xudong YUAN , NAL PHARMACEUTICAL GROUP LIMITED
发明人： Y. Joseph MO , Xudong YUAN
IPC分类号： A61K9/50 , A61K45/06 , A61K31/337
摘要： Nanoparticles and microspheres are provided for delivering an anticancer agent or other active agents to a subject. The nanoparticles and the microspheres are formed from a core that is encased by a coating or shell that includes a somatostatin-albumin fusion protein or analogue thereof. The somatostatin-albumin fusion protein includes at least one albumin (or an analog thereof) moiety, at least one somatostatin moiety (e.g. SST-14, SST-28), and at least one spacer connecting albumin to albumin, somatostatin to somatostatin and/or albumin to somatostatin moieties.

2. 发明申请

US20200155766A1 PRE-FILLED SYRINGE CONTAINING MOXIFLOXACIN 审中-公开
公开(公告)号：US20200155766A1
公开(公告)日：2020-05-21
申请号：US16604486
申请日：2018-04-11
申请人： NAL PHARMACEUTICAL GROUP LIMITED
发明人： Y. Joseph MO , Xudong YUAN
IPC分类号： A61M5/315 , A61K9/00 , A61K9/08 , A61K31/4709 , A61M5/31
摘要： The present invention relates to a pre-filled syringe containing Moxifloxacin has a plunger, a barrel, a needle with gauge, kits having this syringe and the use of the syringe for the administration of Moxifloxacin for postsurgical bacterial endophthalmitis after cataract surgery.

3. 发明申请

US20170002057A1 COMPOSITIONS CONTAINING FUSION PROTEIN OF ALBUMIN AND ANALOGS THEREOF, METHODS FOR MAKING AND USING THE SAME 审中-公开
标题翻译：含有ALBUMIN及其类似物的融合蛋白的组合物，其制备和使用方法
公开(公告)号：US20170002057A1
公开(公告)日：2017-01-05
申请号：US15249346
申请日：2016-08-26
申请人： NAL PHARMACEUTICAL GROUP LIMITED
发明人： Y. Joseph MO , Chun Kwong CHU
IPC分类号： C07K14/765 , C07K7/06
CPC分类号： C07K14/765 , A61K38/00 , C07K14/655 , C07K2319/00
摘要： The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum albumin or a region with a partial amino acid sequence of human serum albumin, wherein linker peptide sequences may be present between somatostatin and somatostatin moieties or somatostatin and albumin moieties. Also disclosed are constructs wherein the somatostatin moiety contains multiple tandem repeats of a somatostatin sequence. In selected embodiments, the orientation of the somatostatin and albumin moieties can be varied, and such sequences may impact the binding and efficacy of the disclosed fusion proteins. Also disclosed are methods of making and using the aforementioned constructs. The somatostatin-albumin fusion protein demonstrated enhanced stability when incubated in rat plasma in vitro and prolonged plasma half-life in vivo compared with free somatostatin.
摘要翻译：本发明涉及人生长抑素（例如SST-14或SST-28）和人血清白蛋白的融合蛋白，其包含与人生长抑素的至少85％同源性的区域和与人血清白蛋白至少85％同源的区域具有人血清白蛋白的部分氨基酸序列的区域，其中接头肽序列可以存在于生长抑素和生长抑素部分或生长抑素和白蛋白部分之间。还公开了其中生长抑素部分含有生长抑素序列的多个串联重复序列的构建体。在选择的实施方案中，生长抑素和白蛋白部分的取向可以变化，并且这些序列可能影响所公开的融合蛋白的结合和功效。还公开了制备和使用上述构建体的方法。生长抑素 - 白蛋白融合蛋白在大鼠血浆中体外培养时的稳定性增强，体内延长血浆半衰期与游离生长抑素相比。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式